within Pharmacolibrary.Drugs.ATC.L;

model L01EM01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.74,
    Cl             = 0.0002483333333333333,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0232,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007833333333333333,
    Tlag           = 19.8,            
    Vdp             = 0.0086,
    k12             = 37.0,
    k21             = 37.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EM01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Idelalisib is an orally administered, selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), used primarily in the treatment of certain hematological malignancies such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). It is approved for use in various regions including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in adult patients with hematologic malignancies after oral administration; population pharmacokinetics derived from clinical studies.</p><h4>References</h4><ol><li><p>Jin, F, et al., &amp; Ramanathan, S (2015). The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. <i>Journal of clinical pharmacology</i> 55(8) 944–952. DOI:<a href=&quot;https://doi.org/10.1002/jcph.504&quot;>10.1002/jcph.504</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25821156/&quot;>https://pubmed.ncbi.nlm.nih.gov/25821156</a></p></li><li><p>Davies, A (2015). Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin&#x27;s lymphoma: an overview of pharmacokinetics and clinical trial outcomes. <i>Expert review of hematology</i> 8(5) 581–593. DOI:<a href=&quot;https://doi.org/10.1586/17474086.2015.1071663&quot;>10.1586/17474086.2015.1071663</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26343890/&quot;>https://pubmed.ncbi.nlm.nih.gov/26343890</a></p></li><li><p>Ramanathan, S, et al., &amp; Kearney, BP (2016). Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib. <i>Clinical pharmacokinetics</i> 55(1) 33–45. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0304-0&quot;>10.1007/s40262-015-0304-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26242379/&quot;>https://pubmed.ncbi.nlm.nih.gov/26242379</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EM01;
